Doctor granted FDA emergency approval to use sofosbuvir/daclatasvir for hepatitis C transplant patient
Dr. Robert Fontana, professor of internal medicine and medical director of liver transplantation at U-M Health System, obtained emergency approval from the federal Food and Drug Administration to give Gholston a treatment that combined two oral antiviral medications, sofosbuvir and daclatasvir.
Drug therapy offers new hope to hepatitis C patients
September 16, 2013 at 1:00 am
The Detroit News
Continue reading @ The Detroit News